Global Oncology Academy

Expanding Cancer Detection: How MCED Testing Complements Standard Screening
Expanding Cancer Detection: How MCED Testing Complements Standard Screening
Project Oncology®
Expanding Cancer Detection: How MCED Testing Complements Standard Screening
- Jennifer Caudle, DO
- Patrick McGill, MD
Long-Term Survival Data in High-Risk NSCLC: Insights from Real-World Practice
Long-Term Survival Data in High-Risk NSCLC: Insights from Real-World Practice
Project Oncology®
Long-Term Survival Data in High-Risk NSCLC: Insights from Real-World Practice
- Jacob Sands, MD
- Joshua K. Sabari, MD
Global Perspectives on Perioperative Immunotherapy in LA HNSCC
Global Perspectives on Perioperative Immunotherapy in LA HNSCC
CME/CE
Global Perspectives on Perioperative Immunotherapy in LA HNSCC
0.25 credits
- Kevin J Harrington, PhD, FRCP, FRCR, FRSB
- Christophe Le Tourneau, MD, PhD
0.25 credits
Monitoring Adverse Events Post-CAR T: The Latest Approaches and Best Practices
Monitoring Adverse Events Post-CAR T: The Latest Approaches and Best Practices
Project Oncology®
Monitoring Adverse Events Post-CAR T: The Latest Approaches and Best Practices
- Charles Turck, PharmD, BCPS, BCCCP
- Evandro Bezerra, MD
Mutational Complexity in ROS1-Positive mNSCLC: Insights from Real-World Practice
Mutational Complexity in ROS1-Positive mNSCLC: Insights from Real-World Practice
Project Oncology®
Mutational Complexity in ROS1-Positive mNSCLC: Insights from Real-World Practice
Rethinking Cancer Screening: The Rationale for Multi-Biomarker MCED Testing
Rethinking Cancer Screening: The Rationale for Multi-Biomarker MCED Testing
Project Oncology®
Rethinking Cancer Screening: The Rationale for Multi-Biomarker MCED Testing
- Brian P. McDonough, MD, FAAFP
- Marie Wood, MD
Improving CAR T Referrals for Large B-Cell Lymphoma: A Path to Better Collaboration
Improving CAR T Referrals for Large B-Cell Lymphoma: A Path to Better Collaboration
Project Oncology®
Improving CAR T Referrals for Large B-Cell Lymphoma: A Path to Better Collaboration
- Charles Turck, PharmD, BCPS, BCCCP
- Forat Lutfi, MD
- Nilanjan Ghosh, MD, PhD
Blood-Based Screening for Colorectal Cancer: Benefits and Limitations
Blood-Based Screening for Colorectal Cancer: Benefits and Limitations
Clinician's Roundtable
Blood-Based Screening for Colorectal Cancer: Benefits and Limitations
- Aasma Shaukat, MD, MPH

Medical News

Medical News
Innovative Strategies in Onconephrology: Managing Checkpoint Inhibitor-Associated Nephritis
08/28/2025
Read more
Medical News
Evolving Paradigms in Breast Cancer: Metabolic Influence
08/28/2025
Read more
Medical News
AI in Radiology: Transforming Imaging Practices and Clinical Workflows
08/28/2025
Read more
Medical News
Natera’s Signatera Data: Advancements in Lung Cancer Profiling
08/27/2025
Read more

See more news

CME/CE

Der Schlüssel zum Erfolg – Die zentrale Rolle von EGFR-Tests
Der Schlüssel zum Erfolg – Die zentrale Rolle von EGFR-Tests
MinuteCE®
Der Schlüssel zum Erfolg – Die zentrale Rolle von EGFR-Tests
1.00 program credit
- Professor ByoungChul Cho
- Keith Kerr, BSc, MB ChB
- Natasha B. Leighl, MD, MMSc
1.00 program credit
MinuteCE®
Maîtriser les tests EGFR et la thérapie ciblée dans le CPNPC avancé : du profilage moléculaire à la maîtrise multidisciplinaire
1.00 credit 10 episodes
- Professor ByoungChul Cho
- Keith Kerr, BSc, MB ChB
- Natasha B. Leighl, MD, MMSc
1.00 credit 10 episodes
Il punto di svolta dei test: superare gli ostacoli all’accesso ai biomarcatori
Il punto di svolta dei test: superare gli ostacoli all’accesso ai biomarcatori
MinuteCE®
Il punto di svolta dei test: superare gli ostacoli all’accesso ai biomarcatori
1.00 program credit
- Professor ByoungChul Cho
- Keith Kerr, BSc, MB ChB
1.00 program credit
Guías vivas: cómo entender las normas locales cambiantes
Guías vivas: cómo entender las normas locales cambiantes
MinuteCE®
Guías vivas: cómo entender las normas locales cambiantes
1.00 program credit
- Professor ByoungChul Cho
- Keith Kerr, BSc, MB ChB
- Natasha B. Leighl, MD, MMSc
1.00 program credit

Clinical Practice

6-Year Outcomes from CheckMate 9LA: Efficacy and Safety Across NSCLC Subgroups
6-Year Outcomes from CheckMate 9LA: Efficacy and Safety Across NSCLC Subgroups
Project Oncology®
6-Year Outcomes from CheckMate 9LA: Efficacy and Safety Across NSCLC Subgroups
- Jacob Sands, MD
- Millie Das, MD
Monitoring Adverse Events Post-CAR T: The Latest Approaches and Best Practices
Monitoring Adverse Events Post-CAR T: The Latest Approaches and Best Practices
Project Oncology®
Monitoring Adverse Events Post-CAR T: The Latest Approaches and Best Practices
- Charles Turck, PharmD, BCPS, BCCCP
- Evandro Bezerra, MD
Integrating MCED Testing in Practice: Best Practices for Enhancing Cancer Screening
Integrating MCED Testing in Practice: Best Practices for Enhancing Cancer Screening
Project Oncology®
Integrating MCED Testing in Practice: Best Practices for Enhancing Cancer Screening
- Brian P. McDonough, MD, FAAFP
- Mylynda Massart, MD, PhD
Assessing Nivolumab + Ipilimumab in mNSCLC: 6-Year Outcomes from CheckMate 9LA
Assessing Nivolumab + Ipilimumab in mNSCLC: 6-Year Outcomes from CheckMate 9LA
Project Oncology®
Assessing Nivolumab + Ipilimumab in mNSCLC: 6-Year Outcomes from CheckMate 9LA
- Jacob Sands, MD
- Martin Dietrich, MD, PhD

Programs

Postcolonoscopy Colorectal Cancer: Optimizing Quality to Reduce Risk
Postcolonoscopy Colorectal Cancer: Optimizing Quality to Reduce Risk
Clinician's Roundtable
Postcolonoscopy Colorectal Cancer: Optimizing Quality to Reduce Risk
- Aasma Shaukat, MD, MPH
Advancing Noninvasive CRC Screening: Exploring an Aptamer-Based Assay
Advancing Noninvasive CRC Screening: Exploring an Aptamer-Based Assay
Project Oncology®
Advancing Noninvasive CRC Screening: Exploring an Aptamer-Based Assay
- Ryan Quigley
- Hallie Blevins, PhD.
- Marlene Mimi Maeusli, PhD.
Large Cell Neuroendocrine Carcinoma Care: A Look at Evolving Approaches
Large Cell Neuroendocrine Carcinoma Care: A Look at Evolving Approaches
Project Oncology®
Large Cell Neuroendocrine Carcinoma Care: A Look at Evolving Approaches
- Balazs Halmos, MD, MS
Differentiating Large Cell Neuroendocrine Carcinoma from Other Lung Cancers
Differentiating Large Cell Neuroendocrine Carcinoma from Other Lung Cancers
Project Oncology®
Differentiating Large Cell Neuroendocrine Carcinoma from Other Lung Cancers
- Balazs Halmos, MD, MS